Table 3. Factors associated with development of dyslipidemia.
| Risk analysisa | ||||||||
| Total cholesterol ≥200 mg/dL | HDL-cholesterol <40 mg/dL | LDL-cholesterol ≥130 mg/dL | Triglycerides ≥200 mg/dL | |||||
| OR (95% CI),univariate analysis | OR (95% CI), multivariateanalysis | OR (95% CI),univariate analysis | OR (95% CI), multivariate analysis | OR (95% CI), univariate analysis | OR (95% CI), multivariate analysis | OR (95% CI),univariateanalysis | OR (95% CI), multivariate analysis | |
| Sex | 1.682 (0.662,4.273) | – | 0.593 (0.212,1.660) | – | 1.261 (0.464,3.424) | – | 2.385 (0.622,9.149) | – |
| Age (years)b | 1.047 (0.998,1.097) | 1.041 (1.016,1.067) | 0.962 (0.913,1.014) | – | 1.033 (0.983,1.087) | – | 0.976 (0.924,1.031) | – |
| HCV | 1.833 (0.678,4.957) | 0.256 (0.075,0.868) | 0.771 (0.261,2.284) | – | 1.913 (0.665,5.503) | – | 1.083 (0.311,3.773) | – |
| CD4+ T-cell count at baseline (every +100 cells/mm3) | 1.000 (0.998,1.001) | – | 1.001 (1.000,1.003) | – | 1.000 (0.999,1.001) | – | 1.000 (0.999,0.002) | – |
| Time since HIVdiagnosis (years) | 1.028 (0.964,1.097) | – | 1.006 (0.938,1.078) | – | 1.028 (0.962,1.099) | – | 0.977 (0.903,1.058) | – |
| Time on treatment (years) | 1.046 (0.962,1.137) | – | 0.946 (0.864,1.036) | – | 1.013 (0.931,1.101) | – | 0.984 (0.889,1.089) | – |
| No. of prior ARV regimens | 1.075 (0.972,1.190) | – | 0.996 (0.901,1.100) | – | 1.065 (0.964,1.177) | – | 1.029 (0.922,1.149) | – |
| ARV drugs used at entry | ||||||||
| TDF | 1.278 (0.532,3.067) | – | 1.259 (0.483,3.282) | – | 1.169 (0.464,2.946) | – | 1.607 (0.552,4.675) | – |
| ABC | 0.267 (0.070,1.021) | – | 4.237 (0.882,20.354) | – | 0.517 (0.158,1.698) | – | 1.994 (0.397,9.518) | – |
| LPV | 1.294 (0.529,3.165) | – | 0.863 (0.317,2.350) | – | 0.888 (0.337,2.340) | – | 1.066 (0.351,3.235) | – |
| ATV | 1.249 (0.438,3.561) | – | 0.143 (0.018,1.161) | – | 1.438 (0.535,3.863) | – | 2.232 (0.581,8.579) | – |
| DRV | 2.611 (0.581,11.736) | – | 0.321 (0.066,1.563) | – | 0.871 (0.181,4.195) | – | 0.370 (0.079,1.735) | – |
Statistically significant results (p<0.05) are in bold.
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C virus; ARV, antiretroviral; TDF, tenofovir; ABC, abacavir; NRTIs, nucleoside reverse transcriptase inhibitors; LPV, lopinavir;
ATV, atazanavir; DRV, darunavir; OR, odds ratio; CI, confidence interval.
a
Univariate and multivariate logistic regression.
b
Risk per year.